219 related articles for article (PubMed ID: 32039795)
1. Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer.
Chen WC; Huang HJ; Chang TC; Chou HH
Taiwan J Obstet Gynecol; 2020 Jan; 59(1):21-27. PubMed ID: 32039795
[TBL] [Abstract][Full Text] [Related]
2. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
Shawky H; Tawfik H; Hewidy M
J Egypt Natl Canc Inst; 2014 Sep; 26(3):139-45. PubMed ID: 25150129
[TBL] [Abstract][Full Text] [Related]
3. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
[TBL] [Abstract][Full Text] [Related]
4. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.
Sharma R; Graham J; Mitchell H; Brooks A; Blagden S; Gabra H
Br J Cancer; 2009 Mar; 100(5):707-12. PubMed ID: 19223898
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
[TBL] [Abstract][Full Text] [Related]
6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
7. The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
Cadron I; Abdulkadir L; Despierre E; Berteloot P; Neven P; Leunen K; Amant F; Vergote I
Gynecol Oncol; 2013 Jan; 128(1):34-37. PubMed ID: 23063762
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
9. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
11. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Fusco N
Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.
González-Martín AJ; Calvo E; Bover I; Rubio MJ; Arcusa A; Casado A; Ojeda B; Balañá C; Martínez E; Herrero A; Pardo B; Adrover E; Rifá J; Godes MJ; Moyano A; Cervantes A
Ann Oncol; 2005 May; 16(5):749-55. PubMed ID: 15817604
[TBL] [Abstract][Full Text] [Related]
16. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
Chan JK; Brady MF; Penson RT; Huang H; Birrer MJ; Walker JL; DiSilvestro PA; Rubin SC; Martin LP; Davidson SA; Huh WK; O'Malley DM; Boente MP; Michael H; Monk BJ
N Engl J Med; 2016 Feb; 374(8):738-48. PubMed ID: 26933849
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
Vergote I; Bergfeldt K; Franquet A; Lisyanskaya AS; Bjermo H; Heldring N; Buyse M; Brize A
Gynecol Oncol; 2020 Feb; 156(2):293-300. PubMed ID: 31826802
[TBL] [Abstract][Full Text] [Related]
18. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO).
Lortholary A; Largillier R; Weber B; Gladieff L; Alexandre J; Durando X; Slama B; Dauba J; Paraiso D; Pujade-Lauraine E;
Ann Oncol; 2012 Feb; 23(2):346-52. PubMed ID: 21562072
[TBL] [Abstract][Full Text] [Related]
20. What is the role of dose-dense therapy?
van der Burg ME; van der Gaast A; Vergote I; Burger CW; van Doorn HC; de Wit R; Stoter G; Verweij J
Int J Gynecol Cancer; 2005; 15 Suppl 3():233-40. PubMed ID: 16343238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]